ID: ALA5207862

Max Phase: Preclinical

Molecular Formula: C21H23Cl2N7O

Molecular Weight: 460.37

Representations

Canonical SMILES:  O=C(N[C@@H]1CCCN(c2ncnc3[nH]ncc23)C1)[C@H](Nc1cc(Cl)cc(Cl)c1)C1CC1

Standard InChI:  InChI=1S/C21H23Cl2N7O/c22-13-6-14(23)8-16(7-13)27-18(12-3-4-12)21(31)28-15-2-1-5-30(10-15)20-17-9-26-29-19(17)24-11-25-20/h6-9,11-12,15,18,27H,1-5,10H2,(H,28,31)(H,24,25,26,29)/t15-,18-/m1/s1

Standard InChI Key:  XXAOWRFSTMLZBO-CRAIPNDOSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 460.37

Molecular Weight (Monoisotopic): 459.1341

AlogP: 3.64

#Rotatable Bonds: 6

Polar Surface Area: 98.83

Molecular Species: NEUTRAL

HBA: 6

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.05

CX Basic pKa: 3.89

CX LogP: 3.28

CX LogD: 3.27

Aromatic Rings: 3

Heavy Atoms: 31

QED Weighted: 0.52

Np Likeness Score: -1.77

References

1. Hopkins BT, Bame E, Bell N, Bohnert T, Bowden-Verhoek JK, Bui M, Cancilla MT, Conlon P, Cullen P, Erlanson DA, Fan J, Fuchs-Knotts T, Hansen S, Heumann S, Jenkins TJ, Gua C, Liu Y, Liu Y, Lulla M, Marcotte D, Marx I, McDowell B, Mertsching E, Negrou E, Romanowski MJ, Scott D, Silvian L, Yang W, Zhong M..  (2021)  Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitors.,  44  [PMID:34314938] [10.1016/j.bmc.2021.116275]

Source

Source(1):

• Scientific Literature